This brief section will provide an overview of the key responsibilities ofprimary-care practitioners in diabetes screening in general, screening for DKDin particular, and providing treatment regimens to optimize cardiorenalprotection, with particular focus on the newer additions to the risk-reductionarmamentarium, SGLT2 inhibitors and finerenone. Here, SLC5A2 is linked to diabetes mellitus.